Huntington's disease: Pathogenesis to animal models

Pharmacological Reports

Volumn 62, Issue 1, 2010, Pages 1-14

  Kumar, Puneet ^a   Kalonia, Harikesh ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Excitotoxicity; Gait abnormalities; Huntington's disease; Memory; Oxidative stress

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE RECEPTOR; CANNABINOID RECEPTOR; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HUNTINGTIN; MALONIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE; QUINOLINIC ACID;

APOPTOSIS; BODY MOVEMENT; BRAIN CORTEX; BRAIN REGION; CELL VIABILITY; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; EXCITOTOXICITY; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; MOLECULAR GENETICS; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; TRANSCRIPTION REGULATION; TRINUCLEOTIDE REPEAT;

EID: 77950857170     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70238-3     Document Type: Review

References (113)

1. Acevedo-Torres K, Berríos L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, Torres-Ramos CA, Ayala-Torres S: Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst), 2009, 8, 126-136.
2. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD, Markel DS et al.: Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med, 1990, 322, 1293-1298.
3. Andreassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF: Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominantnegative mutant. J Neurochem, 2000, 75, 847-852.
4. Ayala A, Venero JL, Cano J, Machado A: Mitochondrial toxins and neurodegenerative diseases. Front Biosci, 2007,12,986-1007.
5. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW: Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci, 1991, 11, 1649-1659.
6. Beal MF, Ferrante RJ: Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci, 2004, 5, 373-384.
7. Becker LI, Miguel RD, Ruzi JJF: The endocannabinoid system and Huntington's disease. Curr Drug Targets-CNS & Neurol Disord, 2003, 2, 335-347.
8. Berliocchi L, Bano D, Nicotera P: Ca signals and death programmes in neurons. Philos Trans R Soc Lond B Biol Sci, 2005, 360, 2255-2258.
9. Blum D, Gall D, Cuvelier L, Schiffmann SN: Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport, 2001, 12, 1769-1772.
10. Bracci E, Centonze D, Bernardi G, Calabresi P: Dopa mine excites fast-spiking interneurons in the striatum. J Neurophysiol, 2002, 87, 2190-2194.
11. Brandt J, Strauss ME, Larus J, Jensen B, Folstein SE, Folstein MF: Clinical correlates of dementia and disability in Huntington's disease. J Clin Neuropsychol, 1984, 6,401-412.
12. Brouillet E, Condé F, Beal MF, Hantraye P: Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol, 1999, 59, 427-468.
13. Browne SE: Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann NY Acad Sci, 2008, 1147, 358-382.
14. Browne SE, Ferrante RJ, Beal MF: Oxidative stress in Huntington's disease. Brain Pathol, 1999, 9, 147-163.
15. Burns A, Folstein S, Brandt J, Folstein M: Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis, 1990, 178, 20-26.
16. Butters N, Sax D, Montgomery K, Tarlow S: Comparison of the neuropsychological deficits associated with early and advanced Huntington's disease. Arch Neurol, 1978,35,585-589.
17. Caboche J, Charvin D: Role of dopamine in Huntington's disease. Med Sci (Paris), 2006, 22, 115-127.
18. Caine ED, Hunt RD, Weingartner H, Ebert MH: Huntington's dementia. Clinical and neuropsychological features. Arch Gen Psychiatry, 1978, 35, 377-384.
19. Caine ED, Shoulson I: Psychiatric syndromes in Huntington's disease. Am J Psychiatry, 1983, 140, 728-733.
20. Calabresi P, Mercuri NB, De Murtas M, Bernardi G: Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum. Neurosci Lett, 1990, 118, 99-102.
21. Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB, Pisani A et al.: Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci, 2003, 23, 6245-6254.
22. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB et al.: Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA, 1998, 95, 6480-6485.
23. Charara A, Heilman TC, Levey AI, Smith Y: Pre- and postsynaptic localization of GABA receptors in the basal ganglia in monkeys. Neuroscience, 2000, 95,127-140.
24. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC et al.: CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem, 2005, 93, 310-320.
25. Cummings JL: Behavioral and psychiatric symptoms associated with Huntington's disease. Adv Neurol, 1995, 65,179-186.
26. Darley FL, Brown JR, Swenson WM: Language changes after neurosurgery for Parkinsonism. Brain Lang, 1975, 2,65-69.
27. Dewhurst K, Oliver JE, McKnight AL: Socio-psychiatric consequences of Huntington's disease. Br J Psychiatry, 1970,116,255-258.
28. Dewhurst K, Oliver J, Trick KL, McKnight AL: Neuropsychiatric aspects of Huntington's disease. Confin Neurol, 1969, 31, 258-268.
29. DiFiglia M: Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci, 1990, 13, 286-289.
30. Dragatsis I, Dietrich P, Zeitlin S: Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse. Neurosci Lett, 2000, 282, 37-40.
31. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P et al.: Inactivation of the mouse Huntington's disease gene homolog Hdh. Science, 1995, 269,407-410.
32. Engelsen B: Neurotransmitter glutamate: its clinical importance. Acta Neurol Scand, 1986, 74, 337-355.
33. Faull RLM, Waldvogel HJ, Nicholson LFB, Synek BJL: The distribution of GABA benzodiazepine receptors in the basal ganglia in Huntington's disease and in quinolinic acid lesioned rats. Prog Brain Res, 1993, 99, 105-123.
34. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB: Selective sparing of a class of striatal neurons in Huntington's disease. Science, 1985, 230, 561-563.
35. Ferrante RJ, Kowall NW, Richardson EP Jr: Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci, 1991, 11, 3877-3887.
36. Ferré S, O'Connor WT, Fuxe K, Ungerstedt U: The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci, 1993, 13, 5402-5406.
37. Folstein MF: Heterogeneity in Alzheimer's disease. Neurobiol Aging, 1989, 10, 434-435.
38. Folstein SE, Jensen B, Leigh RJ, Folstein MF: The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol, 1983, 5, 605-609.
39. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev, 2001, 53, 527-552.
40. Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F: Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis, 2004, 17, 77-88.
41. Gil JM, Rego AC: Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci, 2008, 27, 2803-2820.
42. Girotti F, Marano R, Soliveri P, Geminiani G, Scigliano G: Relationship between motor and cognitive disorders in Huntington's disease. J Neurol, 1988, 235, 454-457.
43. Glass L, Dragunow M, Faull RLM: The pattern of neurodegenration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA receptors alterations in the human basal ganglia in Huntington's disease. Neuroscience, 2000, 97, 505-519.
44. Graybiel AM: Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci, 1990, 13, 244-254.
45. Halliwell B: Reactive oxygen species and the central nervous system. J. Neurochem, 1992, 59, 1609-1623.
46. Hantraye P, Riche D, Maziere M, Isacson O: A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol, 1990, 108, 91-104.
47. Harper PS: The epidemiology of Huntington's disease. Hum Genet, 1986, 89, 365-376.
48. Hassel B, Sonnewald U: Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo. J Neurochem, 1995, 65, 1184-1191.
49. Heathfield KW: Huntington's chorea. Investigation into the prevalence of this disease in the area covered by the North East Metropolitan Regional Hospital Board. Brain, 1967,90,203-232.
50. Hebb C: CNS at the cellular level: identity of transmitter agents. Annu Rev Physiol, 1970, 32, 165-192.
51. Hettinger BD, Lee A, Linden J, Rosin DL: Ultrastructural localization of adenosine A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol, 2001, 431, 331-346.
52. Hickey MA, Chesselet MF: Apoptosis in Huntington's disease. Prog Neuropsypharmacol Biol Psychiatry, 2003, 27,255-265.
53. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ et al.: A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 1999, 23, 181-192.
54. Jacobson KA, Gao ZG: Adenosine receptors as therapeutic targets. Nat Rev Drug Discov, 2006, 5, 247-264.
55. Jakel RJ, Maragos WF: Neuronal cell death in Huntington's disease: a potential role for dopamine. TINS, 2000, 23,239-245.
56. Jarabek BR, Yasuda RP, Wolfe BB: Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain, 2004, 127, 505-516.
57. Jelliffe SE: Acontribution to the history of Huntington's chorea: a preliminary report. Neurographs, 1908, 1, 1116-1124.
58. Jha S, Patel R: Some observations on the spectrum of dementia. Neurol India, 2004, 52, 213-214.
59. Josiassen RC, Curry L, Roemer RA, DeBease C, Mancall EL: Patterns of intellectual deficit in Huntington's disease. J Clin Neuropsychol, 1982, 4, 173-183.
60. Kent A: Huntington's disease. Nurs Stand, 2004, 21, 45-51.
61. Kirkwood SC, Su JL, Conneally P, Foroud T: Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol, 2001, 58, 273-278.
62. Klein J: Woodie Guthrie. A life. Faber and Faber, London, 1981.
63. Kleppner SR, Tobin AJ: GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Expert Opin Ther Targets, 2001, 5, 219-239.
64. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, Squitieri F et al.: A worldwide study of the Huntington's disease mutation. The sensitiv-ity and specificity of measuring CAG repeats. N Engl J Med, 1994, 330, 1401-1406.
65. Lacey CJ, Boyes J, Gerlach O, Chen L, Magill PJ, Bolam JP: GABA receptors at glutamatergic synapses in the rat striatum. Neuroscience, 2005, 136, 1083-1095.
66. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA et al.: Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci, 2001, 21, 9112-9123.
67. Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA: Abnormal ocular motor control in Huntington's disease. Neurology, 1983, 33, 1268-1275.
68. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF: Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci, 2004, 27, 691-697.
69. Li JY, Plomann M, Brundin P: Huntington's disease: a synaptopathy? Trends Mol Med, 2003, 9, 414-420.
70. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E: Calcium homeostasis and mitochon-drial dysfunction in striatal neurons of Huntington dis-ease. J Biol Chem, 2008, 283, 5780-5789.
71. Lundervold AJ, Reinvang I, Lundervold A: Characteristic patterns of verbal memory function in patients with Huntington's disease. Scand J Psychol, 1994, 35, 38-47.
72. Maglione V, Cannella M, Gradini R, Cislaghi G, Squitieri F: Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mech Ageing Dev, 2006, 127, 213-216.
73. Mancuso M, Kiferle L, Petrozzi L, Nesti C, Rocchi A, Ceravolo R, Orsucci D et al.: Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. Neurosci Lett, 2008, 444, 83-86.
74. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M et al.: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 1996, 87, 493-506.
75. Manyam BV, Giacobini E, Colliver JA: Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease. J Neurol, 1990, 237, 281-284.
76. Menalled LB, Chesselet MF: Mouse models of Huntington's disease. Trends Pharmacol Sci, 2002, 23, 32-39.
77. Mitchell IJ, Cooper AJ, Griffiths MR: The selective vulnerability of striatopallidal neurons. Prog Neurobiol, 1999,59,691-719.
78. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA: Role of adenosine A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. Prog Neurobiol, 2007, 83, 293-309.
79. Moses JA Jr, Golden CJ, Berger PA, Wisniewski AM: Neuropsychological deficits in early, middle, and late stage Huntington's disease as measured by the Luria-Nebraska Neuropsychological Battery. Int J Neurosci, 1981,14,95-100.
80. Naarding P, Kremer HPH, Zitman FG: Huntington's disease: a review of the literature on prevalence and treat-ment of neuropsychiatry phenomena. Eur Psychiatry, 2001,16,439-445.
81. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A et al.: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell, 1995, 81, 811-823.
82. Nisenbaum ES, Berger TW, Grace AA: Presynaptic modulation by GABAB receptors of glutamatergic excitation and GABAergic inhibition of neostriatal neurons. J Neurophysiol, 1992, 67, 477-481.
83. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS et al.: Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature, 1999, 399, 263-267.
84. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW et al.: Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain, 2003, 126, 1127-1135.
85. Perez-De La Cruz V, Santamaria A: Integrative hypothesis for Huntington's disease: a brief review of experimental evidence. Physiol Res, 2007, 56, 513-526.
86. Perry TL, Hansen S, Kloster M: Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med, 1973, 288, 337-342.
87. Peyser CE, Folstein SE: Huntington's disease as a model for mood disorders. Clues from neuropathology and neurochemistry. Mol Chem Neuropathol, 1990, 12, 99-119.
88. Picconi B, Passino E, Sgobio C, Bonsi P, Barone I, Ghiglieri V, Pisani A et al.: Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis, 2006, 22,143-152.
89. Podoll K, Caspary P, Lange HW, Noth J: Language functions in Huntington's disease. Brain, 1988, 111, 1475-1503.
90. Qrbeck AL: An early description of Huntington's chorea. Med Hist, 1959, 3, 165-168.
91. Ramaswamy S, McBride JL, Kordower JH: Animal models of Huntington's disease. ILAR J, 2007, 48, 356-373.
92. Reddy HP, Maya W, Danilo AT: Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci, 1999, 22, 248-254.
93. Reed TE, Chandler JH: Huntington's chorea in Michigan. I. Demography and genetics. Am J Hum Genet, 1958,10,201-225.
94. Reynolds GP, Pearson SJ; Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci Lett, 1987, 78, 233-238.
95. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E et al.: Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci, 2000,20,3705-3713.
96. Roberts TJ: 3-Nitropropionic acid model of metabolic stress: assessment by magnetic resonance imaging. Methods Mol Med, 2005, 104, 203-220.
97. Rothman SM, Olney JW: Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci, 1995,18,57-58.
98. Roze E, Betuing S, Deyts C, Vidailhet M, Caboche J: Pathophysiology of Huntington's disease: an update. Rev Neurol (Paris), 2008, 164, 977-994.
99. Sanberg PR, Calderon SF, Giordano M, Tew JM, Norman AB: The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp Neurol, 1989, 105, 45-53.
100. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ: Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett, 1991, 16, 130, 177-1781.
101. Schoenfeld M, Myers RH, Cupples LA, Berkman B, Sax DS, Clark E: Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry, 1984, 47, 1283-1287.
102. Schwarcz R, Bennett JP Jr, Coyle JT: Inhibitors of GABA metabolism: implications for Huntington's disease. Ann Neurol, 1977, 2, 299-303.
103. Schwarcz R, Foster AC, French ED, Whetsell WO Jr, Köhler C: Excitotoxic models for neurodegenerative disorders. Life Sci, 1984, 35, 19-32.
104. Smith Y, Bennett BD, Bolam JP, Parent A, Sadikot AF: Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. J Comp Neurol, 1994, 344, 1-19.
105. Spina MB, Cohen G: Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA, 1989, 86, 1398-1400.
106. Teunissen CE, Steinbusch HW, Angevaren M, Appels M, de Bruijn C, Prickaerts J, de Vente J: Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. Neuroscience, 2001, 105, 153-167.
107. Varani K, Rigamonti D, Sipione S, Camurri A, Borea PA, Cattabeni F, Abbracchio MP, Cattaneo E: Aberrant amplification of A receptor signaling in striatal cells expressing mutant huntingtin. FASEB J, 2001, 15, 1245-1247.
108. Wang H, Lim PJ, Karbowski M, Monteiro MJ: Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet, 2009, 18, 737-752.
109. Webb M, Trzepacz PT: Huntington's disease: correlations of mental status with chorea. Biol Psychiatry, 1987, 22,751-761.
110. Wong PT, McGeer PL, Rossor M, McGeer EG: Ornithine aminotransferase in Huntington's disease. Brain Res, 1982,231,466-471.
111. Yin HH, Knowlton BJ: The role of the basal ganglia in habit formation. Nat Rev Neurosci, 2006, 7, 464-476.
112. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB: NMDA receptor losses in putamen from patients with Huntington's disease. Science, 1988, 241, 981-983.
113. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A: Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet, 1995, 11, 155-163.